A significant trend is the strong focus on immune checkpoint bispecific targets, particularly PD1‐CTLA4 ( n = 216 trials, 31.7%, 4 BsAbs), PD1‐VEGF ( n = 56 trials, 8.2%, 3 BsAbs), followed by oncogene targets like EGFR‐MET ( n = 34 trials, 5%, 3 BsAbs).
← all excerpts
The Landscape of Bispecific Antibodies in Solid Tumor Oncology: Trends, Challenges, and Opportunities.
1
—
—